VRT106 with Camrelizumab and Apatinib for Advanced Liver Cancer
Treatments studied
Part of Cancer clinical trials.
This study tests a combination of three drugs—VRT106 (a new oncolytic virus therapy), camrelizumab (an immune-boosting drug), and apatinib (a targeted cancer drug)—to treat advanced hepatocellular carcinoma (HCC), a type of liver cancer. The goal is to see if this combination works better than standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Between 18 and 75 years old
- Confirmed advanced liver cancer (HCC) diagnosis by biopsy or imaging
- Good overall health status (able to do light activity)
- Expected to live at least 3 more months
- No severe problems with blood counts, liver, kidneys, blood clotting, or heart function
- Never received camrelizumab, apatinib, oncolytic virus therapy, or gene therapy before
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two immunotherapy drugs, TACE (a procedure to block blood flow to tumors), and lenvatinib (a targeted therapy) for people with liver cancer that has not responded to initial treatment. It aims to see if this combination can help shrink tumors or slow cancer growth.
This trial tests a combination of radioactive microspheres (Yttrium-90) with targeted immunotherapy drugs (camrelizumab and apatinib) for people with liver cancer (HCC) that cannot be surgically removed. It may be an option for those with intermediate-stage disease who haven't had prior systemic therapy.
This trial tests a combination of two drugs (camrelizumab and apatinib) with or without standard chemotherapy for advanced liver cancer that cannot be treated with surgery or has gotten worse after local treatments. The goal is to see if the combination helps control the cancer better.
This study tests whether a combination of chemotherapy (FOLFOX) plus two immunotherapy drugs (Camrelizumab and Apatinib) works better when given directly into the liver artery (HAIC) versus through a vein. It's for people with advanced liver cancer who haven't had other treatments yet.
This trial tests a combination of radiation therapy, an immunotherapy drug called camrelizumab, and a targeted therapy pill called apatinib for people with advanced liver cancer that has spread to the main blood vessel of the liver. The goal is to see if this triple therapy can shrink tumors and improve outcomes.
This study tests a personalized combination treatment for unresectable (cannot be removed with surgery) liver cancer. It uses a special test to guide which drugs you receive, aiming to improve how well the treatment works for your specific tumor type.
Hear when a new HCC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.